Cardiff Oncology, Inc. financial data

Symbol
CRDF on Nasdaq
Location
11055 Flintkote Avenue, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Jul 29, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 556 % -17%
Debt-to-equity 22.5 % +18.8%
Return On Equity -77.9 % -24.4%
Return On Assets -63.7 % -20.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 66.5M shares +42.9%
Common Stock, Shares, Outstanding 66.5M shares +45.9%
Entity Public Float 99.1M USD +54%
Common Stock, Value, Issued 7K USD +40%
Weighted Average Number of Shares Outstanding, Basic 66.5M shares +48.4%
Weighted Average Number of Shares Outstanding, Diluted 66.5M shares +48.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 545K USD -18%
Operating Income (Loss) -54.3M USD -21.7%
Nonoperating Income (Expense) 3.31M USD -12.2%
Net Income (Loss) Attributable to Parent -51M USD -24.9%
Earnings Per Share, Basic 0 USD/shares +3.3%
Earnings Per Share, Diluted 0 USD/shares +3.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10.8M USD -57.7%
Cash, Cash Equivalents, and Short-term Investments 71M USD +17.7%
Accounts Receivable, after Allowance for Credit Loss, Current 526K USD +16.6%
Assets, Current 73.7M USD +18.4%
Property, Plant and Equipment, Net 743K USD -32.1%
Operating Lease, Right-of-Use Asset 899K USD -37.5%
Other Assets, Noncurrent 401K USD -68.5%
Assets 75.7M USD +14.7%
Accounts Payable, Current 6.01M USD +17.7%
Employee-related Liabilities, Current 2.25M USD +25.4%
Accrued Liabilities, Current 9.94M USD +48.1%
Liabilities, Current 16.7M USD +33.1%
Operating Lease, Liability, Noncurrent 464K USD -59.3%
Liabilities 17.1M USD +25.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 17K USD
Retained Earnings (Accumulated Deficit) -412M USD -14.2%
Stockholders' Equity Attributable to Parent 58.6M USD +11.9%
Liabilities and Equity 75.7M USD +14.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.8M USD -65.3%
Net Cash Provided by (Used in) Financing Activities 107K USD
Net Cash Provided by (Used in) Investing Activities -14.6M USD -415%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 66.5M shares +45.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -27.4M USD -813%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 10.8M USD -57.7%
Deferred Tax Assets, Valuation Allowance 48.4M USD +23.6%
Deferred Tax Assets, Gross 48.7M USD +23.1%
Operating Lease, Liability 1.52M USD -29.1%
Depreciation 94K USD -10.5%
Payments to Acquire Property, Plant, and Equipment 80K USD +900%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -50.9M USD -25.6%
Lessee, Operating Lease, Liability, to be Paid 1.64M USD -31.5%
Property, Plant and Equipment, Gross 5.07M USD +0.36%
Operating Lease, Liability, Current 721K USD +2.71%
Lessee, Operating Lease, Liability, to be Paid, Year Two 796K USD +2.71%
Lessee, Operating Lease, Liability, to be Paid, Year One 710K USD +2.75%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 119K USD -52.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 136K USD -82.9%
Deferred Tax Assets, Operating Loss Carryforwards 27.4M USD +16.8%
Preferred Stock, Shares Authorized 20M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 136K USD -82.9%
Operating Lease, Payments 730K USD +1.96%
Additional Paid in Capital 470M USD +13.8%
Depreciation, Depletion and Amortization 93K USD -8.82%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 5.51M USD +32.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares